feature photo

 

Press Releases and Other Research News

 

IMPAACT 2010/VESTED Completed Accrual

February 8, 2019

The IMPAACT Network is thrilled to report that IMPAACT 2010/VESTED has successfully completed accrual into the study, as of 8 February 2019. Congratulations to all 22 sites that enrolled participants in Zimbabwe, South Africa, Uganda, Brazil, Botswana, Tanzania, Thailand, the United States, and India!



IMPAACT Network Leadership Election Announcement

Network Leadership Announcement

December 18, 2018

The Network is pleased to announce the re-election of Dr. Sharon Nachman as IMPAACT Network Chair and the election of Dr. Philippa Musoke as International Vice Chair and Dr. Patricia Flynn as US Domestic Vice Chair. The terms of service for the elected Chair and Vice Chairs will begin on 1 December 2020, assuming the grant application submitted for continuation of the network is successful.

>> Read here



Reflections on the Past Year

P1026s

December 1, 2018

A World AIDS Day Message from IMPAACT Chair Sharon Nachman and IMPAACT Vice-Chair James McIntyre with a recap of 2018 Network milestones.

>> Read here



IMPAACT Manual of Procedures Updated

P1026s

November 28, 2018

The IMPAACT Network has updated and finalized several new sections of the Network Manual of Procedures (MOP). Individual sections are available on the website at https://impaactnetwork.org/resources/policies-procedures.htm along with a document summarizing recent changes and updates. A combined version of all MOP sections and summary of changes is available here.

Please let the Operations Center know if you have any questions about the new and updated documents or issues accessing the files. Please distribute this information widely, as applicable, and ensure awareness and availability of these documents.



P1026s EVG data used to change Stribild® and Genvoya® labels

P1026s

November 15, 2018

IMPAACT P1026s has now enrolled over 1000 pregnant/postpartum women for intensive pharmacokinetic (PK) sampling of HIV, TB and contraceptive medications and is a widely recognized repository of pregnancy pharmacokinetic data. IMPAACT P1026s has published data describing the safety and PK of over 20 antiretrovirals and its data have served as a key source in dosing recommendations issued by perinatal HIV guidelines committees, including the US Perinatal HIV Guidelines Committee and WHO.

>> Read more

NIAID has also issued a press release related to P1026s, which can be accessed at this link.


Call for Nominations - IMPAACT Network Chair and Two Network Vice Chairs

Chair nominations

November 13, 2018

The IMPAACT Network is now accepting nominations for Network Chair and two Network Vice Chair positions. See the calls for nomination below for more information.

>> IMPAACT Network Chair
>> International Network Vice Chair and US Domestic Network Vice Chair

Please direct questions to IMPAACTops@fhi360.org.


IMPAACT at the 2018 Union World Conference on Lung Health

Union 2018

November 1, 2018

Members of the IMPAACT Tuberculosis (TB) Scientific Committee and representatives of several study teams chaired sessions and presented important outcomes, updates and proposals for the future TB research agenda at the 49th Union World Conference on Lung Health in The Hague, the Netherlands, on 24-27 October 2018.

More details on the network’s contributions at the conference are available here.


WHO Toolkit

WHO Toolkit

July 23, 2018

IMPAACT has partnered with the World Health Organization (WHO) and other organizations to develop a toolkit for the research and development of pediatric antiretroviral drugs and formulations. WHO’s launch of the toolkit coincided with the AIDS 2018 Conference in Amsterdam. It can be accessed here.



IMPAACT at AIDS 2018

AIDS 2018

July 11, 2018

The IMPAACT Network is pleased to announce that 5 abstracts as posters and 3 abstracts as oral presentations have been accepted to AIDS 2018. Seven abstracts will also be presented as oral and poster presentations at the HIV Pediatrics Workshop proceeding AIDS 2018.

To view the full listing, click here.



New study suggests risk of birth defects in babies born to women who were taking dolutegravir at time of conception

May 18, 2018

Preliminary results from an ongoing observational study in Botswana indicate that infants of HIV-infected women taking dolutegravir (DTG) at the time of conception may be at increased risk of neural tube defects. The same study provides no evidence of an increased risk among infants born to women who initiated DTG treatment during pregnancy. Several organizations have issued statements related to these findings, as listed and linked below.

The safety of IMPAACT study participants is of paramount importance to the network and our collaborating partners. The network leadership, including our NIH partners, and the protocol teams for IMPAACT studies of DTG are actively discussing appropriate actions to be taken in response to the new findings. More information and relevant materials will be shared with the sites conducting these studies as soon as decisions are made. In the meantime, any questions should be directed to the respective protocol chairs.

• World Health Organization (WHO): http://www.who.int/medicines/publications/drugalerts/Statement_on_DTG_18May_2018final.pdf?ua=1

• European Medicines Agency (EMA): http://www.ema.europa.eu/ema/index.jsp?

• United States Food and Drug Administration (US FDA): https://www.fda.gov/Drugs/DrugSafety/ucm608112.htm

• United States President’s Emergency Plan for AIDS Relief (PEPFAR): https://www.pepfar.gov/press/releases/282221.htm

• United States Health and Human Services (HHS) Antiretroviral Guidelines Panels: https://aidsinfo.nih.gov/news/2094/statement-on-potential-safety-signal-in-infants-born-to-women-taking-dolutegravir


Study results for IMPAACT P1078 presented at CROI 2018

March 7, 2018

P1078_CROI2018

The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network is delighted to announce the presentation of the study results and important findings from IMPAACT P1078 (TB APPRISE), a phase IV, randomized, double-blind, placebo-controlled trial to evaluate the safety of immediate versus deferred isoniazid preventive therapy (IPT) among HIV-infected women in high tuberculosis (TB) incidence settings, at the 2018 annual Conference on Retroviruses and Opportunistic Infections (CROI) in Boston, Massachusetts.

Read More


Late Breaker Accepted CROI 2018 Abstracts

CROI2018 February 6, 2018

The IMPAACT Network is pleased to announce that one late breaker abstract was accepted as an oral presentation in addition to 11 abstracts as posters and 2 abstracts as oral presentations have been accepted at the 25th Annual Conference on Retroviruses and Opportunistic Infections (CROI). To view the full listing, click here.

Updated 13 March: See all IMPAACT posters and presentations at CROI 2018

 


VESTED/IMPAACT 2010 Now Enrolling!

2010January 19, 2018

The IMPAACT Network is thrilled to report that the first participants have enrolled into VESTED/IMPAACT 2010, as of 19 January 2018. Congratulations to the St. Mary’s and Seke North sites (30303 and 30306) in Zimbabwe for leading the way!

NIAID has also issued a press release related to VESTED beginning enrollment, which can be accessed at this link.




>> Read more from previous years in our News Archive

Funded by the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health of the US National Institutes of Health, US Department of Health and Human Services.